| Ytd | -28.34% | |
| 1y | -47.67% |
| Open | Prev Close | 2.25 | Low | High | Mkt Cap | 229.17M | |||
| Vol | 0.00 | Avg Vol | 997.03K | EPS | -2.69 | P/E | -0.84 | Forward P/E | -1.50 |
| Beta | 1.07 | Short Ratio | 11.83 | Inst. Own | 99.46% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 2.40 | 200-d Avg | 3.55 | 1yr Est | 10.00 |
SLRN News
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical b
ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today ACELYRIN Urges Stockholders t
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockh
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchang
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and th
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, M
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and th
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law vi
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t
NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), ha
MILWAUKEE--(BUSINESS WIRE)--Ademi & Fruchter LLP is investigating ACELYRIN (Nasdaq: SLRN) for possib
Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis o
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tues
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demons
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve
Acelyrin, Inc. (NASDAQ:SLRN ) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participant
On Wednesday, 311 stocks hit new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Wednesday's session, 212 companies made new 52-week lows.